Skip to main content
SpringerLink
Log in

Pankreaskarzinom

  • Chapter
Therapiekonzepte Onkologie

  • 32 Accesses

Zusammenfassung

Diagnosestellung mittels Ultraschall- oder CT-gesteuerter Feinnadelbiopsie, ggf. ERCP, selektive Angiographie. Tumormarker Ca 19–9 in ca. 80% erhöht.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Brennan MF, Kinsella T, Friedman M (1989) Cancer of the Pancreas. In: DeVita V, Heilman S, Rosenberg SA (eds) Cancer. Principles and Practice of Oncology. Lippincott Company, Philadelphia, 800–834

    Google Scholar 

  2. UICC (1990) TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. Spiess) B et al (eds). Springer, Berlin Heidelberg New York, 126–133

    Google Scholar 

  3. Gudjonsson B (1987) Cancer of the Pancreas. 50 Years of Surgery. Cancer 60: 2284–2303

    Article  PubMed  CAS  Google Scholar 

  4. Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally unresectable pancreatic carcinoma: A randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5 fluorouracil) and high dose radiation + 5 fluorouracil. Cancer 48: 1705–1716

    Article  PubMed  CAS  Google Scholar 

  5. Schein PS, Smith FP, Dritschillo A et al. (1983) Phase I—II trial of combined modality FAM (5fluorouracil, Adriamycin and mitomycin-C) plus split course radiation (FAM-RT-FAM) for locally edvanced gastric (LAG) and pancreatic (LAP) cancer: A Mid-Atlantic Oncology Program study. Proc Am Soc Clin Oncol 2: 216 (abstr)

    Google Scholar 

  6. Whittington R, Solin L, Mohiuddin M et al. (1984) Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54: 1991–1998

    Article  PubMed  CAS  Google Scholar 

  7. The Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56: 2563–2568

    Article  Google Scholar 

  8. Klaassen DJ, Maclntyre JM, Catton GE et al. (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. — An Eastern Cooperative Oncology Group Study. J Clin Oncol 3: 373–378

    PubMed  CAS  Google Scholar 

  9. Cohen L, Woodruff KH, Hendrickson FR et al. (1985) Response of pancreatic cancer to local irradiation with highenergy neutrons. Cancer 56: 1235–1241

    Article  PubMed  CAS  Google Scholar 

  10. Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiation) to chemotherapy alone. J Natl Cancer Inst 80: 751–755

    Article  Google Scholar 

  11. Wagener DJT, van Hoessel QCGM, Yap SH, Hoogenraad WJ et al. (1989) Phase II trial of 5fluorouracil, adriamycin and cisplatin (FAP) followed by irradiation and 5-fluorouracil in locally advanced pancreatic cancer. Cancer Chemoth Pharmacol 25: 131–134

    Article  CAS  Google Scholar 

  12. Kamthan A, Morris JC, Chesser MR et al. (1992) Combined modality therapy for effective local control in stage II and Ill pancreatic carcinoma. Proc Am Soc Clin Oncol 11: 160 (abstr)

    Google Scholar 

  13. Wagener D, Rougier P, Wils J et al. (1992) Combined chemoradiotherapy for locally advanced pancreatic cancer (LAPC). Proc Am Soc Clin Oncol 11: 166 (abstr)

    Google Scholar 

  14. Komaki R, Wadler S, Peters MS et al. (1992) High-dose local irradiation plus prophylactic hepatic irradiation for inoperable adenocarcinoma of the pancreas. Cancer 69: 2807–2812

    Article  PubMed  CAS  Google Scholar 

  15. Kaiser MH, Ellenberg SS (1985) Pancreatic Cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120: 899–903

    Google Scholar 

  16. Carter SK, Comis RL (1975) Adenocarcinoma of the pancreas: Current therapeutic approaches, prognostic variables, and criteria of response. In: Cancer Therapy Prognostic Factors and Criteria of Response. Staquet MJ (eds). Raven Press, New York, 237–253

    Google Scholar 

  17. Smith FP, Schein PS (1979) Chemotherapy of pancreatic cancer. Semin Oncol 6: 368–377

    PubMed  CAS  Google Scholar 

  18. Loehrer PJ, Williams SD, Einhorn LH et al. (1985) Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3: 367–372

    Google Scholar 

  19. Bernard S, Noble S, Wilkosky T et al. (1986) A phase II study of ifosfamide (IFOS) plus n-acetyl cysteine (NAC) in metastatic measurable pancreatic adenocarcinoma (PC). Proc. Am Soc. Clin Oncol 5: 84 (abstr)

    Google Scholar 

  20. Ajani JA, Abbruzzese JL, Goudeau P et al. (1988) Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 6: 1703–1707

    PubMed  CAS  Google Scholar 

  21. The Gastrointestinal Tumor Study Group (1989) Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 64: 2010–2013

    Article  Google Scholar 

  22. Wils J, Kok T, Wagener DJT et al. (1993) Phase II trial with ifosfamide in pancreatic cancer. Eur J Cancer 29 A: 290

    Google Scholar 

  23. Wils J, Bleiberg H, Blíjham G et al. (1985) Phase lI study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21: 191–194

    Article  PubMed  CAS  Google Scholar 

  24. Hochster H, Green MD, Speyer JL et al. (1986) Activity of epirubicin in pancreatic carcinoma. Cancer Treat Rep 70: 299–300

    PubMed  CAS  Google Scholar 

  25. Gastrointestinal Tumor Study Group (1987) Phase II trials of single agents Baker’s antifol, diâziquone, and epirubicin in advanced pancreatic cancer. Cancer Treat Rep 71: 865–867

    Google Scholar 

  26. Loven D, Figer A, Vigler N et al. (1989) Epirubicin in the treatment of advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 8: 113 (abstr)

    Google Scholar 

  27. Wils J, Kok T, Wagener DJT et al. (1993) Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 29A: 203–204

    Article  Google Scholar 

  28. Wils JA (1991) Chemotherapy in pancreatic cancer: a rational pursuit? Anti-Cancer Drugs 2: 3–10

    Article  PubMed  CAS  Google Scholar 

  29. Frey C, Twomey P, Keahn R et al. (1981) Randomized study of 5-FU and CCNU in pancreatic cancer. Cancer 47: 27–31

    Article  PubMed  CAS  Google Scholar 

  30. Bukowski RM, Balcerzak SP, O’Bryan RM et al. (1983) Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer 52: 1577–1582

    Article  PubMed  CAS  Google Scholar 

  31. Cullinan SA, Moertel CG, Fleming TR et al (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061–2067

    Article  PubMed  CAS  Google Scholar 

  32. Oster MW, Gray R, Panasci L, Perry MC et al. (1986) Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin and mitomycin ( FSM ). Cancer 57: 29–33

    Google Scholar 

  33. The Gastrointestinal Tumor Study Group (1986) Phase lI studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin c and two regimens of streptozotocin plus mitomycin c plus fluorouracil. J Clin Oncol 4: 1794–1798

    Google Scholar 

  34. Hudis C, Kelsen D, Dougherty J et al. (1990) A randomized trial of streptozotocin (S), mitomycin (M), and 5-fluorouracil (F) (SMF) vs. cisplatin (P), ara-c (A) and coffeine (C) (CAC) in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 9: 107 (abstr)

    Google Scholar 

  35. Cullinan S, Moertel C, Wieand H et al. (1990) A phase Ill trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65: 2207–2212

    Article  PubMed  CAS  Google Scholar 

  36. Hansen R, Quebbeman E, Ritch P et al. (1988) Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 295: 91–93

    Article  PubMed  CAS  Google Scholar 

  37. Vaughn C, Chapman J, Chinn B et al. (1989) Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of the pancreas. Am J Clin Oncol 12: 49–52

    Article  PubMed  CAS  Google Scholar 

  38. DeCaprio JA, Arbuck SG, Mayer RJ (1989) Phase lI study of weekly 5-fluorouracil (5-FU) and folinic acid (FA) in previously untreated patients with unresectable, measurable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 5: 100 (abstr)

    Google Scholar 

  39. Schilder RJ, Paul AR, Walczak J et al. (1990) Phase II trial of PALA/5-fluorouracil in pancreatic cancer. Proc Am Soc Clin Oncol 9: 109 (abstr)

    Google Scholar 

  40. Basile M, Rougier P, Ducreux M et al. (1991) A phase II study of 5-FU continuous infusion (CI) and CDDP (P) in measurable advanced carcinoma of the pancreas (PC). Proc Am Soc Clin Oncol 10: 149 (abstr)

    Google Scholar 

  41. Crown J, Casper ES, Botet J et al. (1991) Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9: 1682–1686

    PubMed  CAS  Google Scholar 

  42. Rothman H, Cantrell JE, Lokich J et al. (1991) Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Cancer 68: 264–268

    Article  PubMed  CAS  Google Scholar 

  43. Tian E, Ardalan B, Benedetto P et al. (1992) A phase II study of short term protracted infusion high dose 5-fluorouracil (5-FU) with leucovorin (LV) and low dose phosphonacetyl-I-aspartic acid (PALA) in pancreatic carcinoma. Proc Am Soc Clin Oncol 11: 184 (abstr)

    Google Scholar 

  44. Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006–2010

    Article  Google Scholar 

Download references

Authors
  1. J. Wils
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wils, J. (1993). Pankreaskarzinom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10495-8_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10495-8_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-56872-8

  • Online ISBN: 978-3-662-10495-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation